Please ensure Javascript is enabled for purposes of website accessibility

Why Co-Diagnostics Stock Is Skyrocketing Today

By Keith Speights - Sep 8, 2020 at 11:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good news could be fueling a short squeeze.

What happened

Shares of Co-Diagnostics (CODX -2.42%) were skyrocketing 35.4% higher as of 11:19 a.m. EDT on Tuesday. The big gain came after the company announced that it had entered into an agreement with Arches Research, a subsidiary of Polarity TE (PTE 3.85%), to expand Arches' use of Co-Diagnostics' Logix Smart COVID-19 test. 

So what

No financial details of the agreement between Co-Diagnostics and Arches Research were announced. So why did Co-Diagnostics' shares jump so much higher?

COVID-19 printed on blue background with two small red coronavirus models

Image source: Getty Images.

We could be seeing the signs of a short squeeze. As of Aug. 14, 2020, nearly 24% of Co-Diagnostics' outstanding shares were sold short. This percentage could be even higher after Abbott Laboratories announced FDA emergency use authorization in late August for its $5 COVID-19 antibody test that can deliver results within 15 minutes.

But Co-Diagnostics' announcement today underscores that its Logix Smart COVID-19 test continues to enjoy solid demand. Arches Research first began using Co-Diagnostics' COVID-19 tests earlier this year. In a statement, Co-Diagnostics CEO Dwight Egan said, "Arches has been an important customer in the ongoing battle against the coronavirus, and we expect this agreement will also create opportunities for sales of additional molecular diagnostic products in our development pipeline, including our upcoming Logix Smart Flu A/Flu B/COVID-19 test kit."

This good news could be causing some short-sellers to cover their positions in Co-Diagnostics. When that happens, it creates an environment that can lead to the kind of surge for the healthcare stock that we're seeing today.

Now what

Investors could learn more about how Co-Diagnostics' business is performing when Egan speaks at H.C. Wainwright's 22nd Annual Global Investment Conference on Sept. 14. In the meantime, any good news for the company could translate to disproportionately large moves for the stock if short-sellers head for the hills en masse.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
$6.46 (-2.42%) $0.16
Abbott Laboratories Stock Quote
Abbott Laboratories
$110.49 (0.20%) $0.22
PolarityTE, Inc. Stock Quote
PolarityTE, Inc.
$1.62 (3.85%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.